SOTERIA and CureMatch Partner to Support Oncologists with Personalized Cancer Treatment Options
SAN DIEGO, CA – April 25 , 2018: SOTERIA Precision Medicine Advisory, Inc. and CureMatch, Inc. have entered into an agreement that will facilitate the delivery of Personalized Combination Therapy® options to the global cancer care community. SOTERIA, the premier concierge precision medicine advisory company, provides client guidance related to individualized tumor profiling services. In turn, CureMatch evaluates a patient’s sequencing data and prior drug history to rank the top mono-therapies, two-drug combinations, and three-drug combinations along with any specifically selected treatment options for the oncologists’ consideration.
“Next-generation tumor sequencing offers insights into the unique biological basis of each individual’s cancer,” stated Aaron Miller, M.D., Ph.D. from UC San Diego Moores
Cancer Center. “Soteria and CureMatch are optimizing the implications of these tests, creating tangible value for oncologists and their patients.”
“SOTERIA is proud to work with CureMatch, the leader in predictive analytics for targeted combination cancer treatment,” stated Julia Civardi, Chief Executive Officer of SOTERIA. “This partnership empowers oncologists with specific treatment recommendations from a molecular basis, so patients receive truly personalized precision medicine.”
“CureMatch is delighted that SOTERIA will help more cancer patients access Personalized Combination Therapy,” stated Stephane Richard, Ph.D, President and Chief Executive Officer of CureMatch.
“Selecting the most promising combinations of anticancer drugs for each individual can be a daunting task, but CureMatch streamlines over 4.5 million drug combinations into actionable analysis for oncologists.”
Chief Science Officer of SOTERIA, Dr. Ashley Brenton, adds, “We have already had tremendous success using CureMatch’s custom analytics to offer personalized, targeted combination therapies for a number of our clients. In many cases, these are patients for whom frontline cancer therapy failed. We look forward to this partnership facilitating therapeutic decision-making in oncology.”
The strategic SOTERIA-CureMatch partnership exemplifies a new way of thinking about cancer care. Instead of traditional tumor site-based treatment, genomics-based precision medicine allows oncologists to target the specific molecular aberrations involved in a patient’s unique cancer.
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com
About SOTERIA Precision Medicine Advisory
SOTERIA provides patients and physicians with the answers and information they need to navigate the rapidly changing landscape of precision medicine. SOTERIA works on behalf of its international clientele to: identify optimal, personalized genetic testing and genomic sequencing options, provide context and meaning to DNA reports and data, optimize the collection and use of biological specimens and raw sequence data, and to facilitate communication between hospitals, research institutions, and biotechnology companies, on a global basis. Privately-held SOTERIA is headquartered in San Diego, CA. For additional information, visit soteriaone.com
CureMatch Media Contact:
Name: Larissa Anderson
Phone: (858) 859-2873
SOTERIA Media Contact:
Name: Jayna Athas
Phone (858) 539-6004
View the official press release here.